Despite important advances in the treatment of multiple sclerosis (MS) over recent years, the
introduction of several disease-modifying therapies (DMTs), the burden of progressive …

Using the term of progressive multiple sclerosis (PMS), we considered a combined
population of persons with secondary progressive MS (SPMS) and primary progressive MS …

Introduction As neurodegeneration is recognized as a major contributor to disability in
multiple sclerosis (MS), brain atrophy quantification could have a high added value in …

Background: Changes in gray matter (GM) volume may be a useful measure of tissue loss in
multiple sclerosis (MS). Objectives: To investigate the rate, patterns, and disability correlates …

Gray matter pathology is an important aspect of multiple sclerosis (MS) pathogenesis and
disease progression. In a recent study, we were able to demonstrate that the higher myelin …

Evidence suggests that sex/gender is an important factor for understanding multiple
sclerosis (MS) and that some of its neuropathological consequences might manifest earlier …

Disability in multiple sclerosis (MS) patients is associated with white matter (WM) and gray
matter (GM) pathology, and both processes contribute differently over the disease course …

This article evaluates the most relevant state‐of‐the‐art magnetic resonance (MR)
techniques that are clinically available to investigate multiple sclerosis (MS). The presence …

Several MRI contrast agents (CAs) are used in medical diagnosis that gadolinium (Gd3+) is
the most widely used as contrast agents. Unfortunately, its toxicity is due to its inefficiency. In …

Background Multiple sclerosis (MS) is an autoimmune disease characterised by
inflammatory damage to the central nervous system (CNS). Accumulated CNS injury can be …